Literature DB >> 17096304

[Epidemiology of hypertension in Germany. Selected results of population-representative cross-sectional studies].

H Löwel1, C Meisinger, M Heier, H Hymer, D Alte, H Völzke.   

Abstract

BACKGROUND AND OBJECTIVES: The mortality rate from cardiovascular disease is higher in northern than southern Germany. To illuminate this further current epidemiological data on arterial hypertension were obtained and compared with previously collected data.
METHODS: The results were based on interview and measurement data of 25- to 64 year-old participants in the Study of Health in Pomerania (SHIP-0 1997 - 2001; n = 3,042), and three population-representative surveys in the region of Augsburg, Southern Germany (MONICA S2 1989/90 n = 3,966; MONICA S3 1994/95 n = 3,916; S4 1999-2001 [KORA-2000 n = 3,464]). Hypertension was defined according to the WHO/ISH guidelines as blood pressure levels of > or =140/90 mmHg or antihypertensive medication given the subjects with known hypertension. Antihypertensive medication was classified as recommended by the German Hypertension Society.
RESULTS: Currently, 57 % (95 % confidence intervall [CI] 54-59 %) of men and 32 % (CI 30-35) of women in Pomerania had hypertension compared to 36 % (CI 34-38 %) and 23 % (CI 21-25 %) in KORA-2000 with some decreases since MONICA S2 und S3. Although a significantly higher prevalence was found in the north than in the south, the medical care was equally poor in both regions: 44-46 % of men and 29-31 % of women were not aware of their hypertension. Among the hypertensives, only 26-31 % of males and 44-48 % of females were being treated for hypertension, mostly with beta blockers, ACE-inhibitors, calcium antagonists, diuretics and AT(1)-antagonists, at least half being given just one of these drugs. Fewer than half of the treated hypertensives were normotensive, regardless of the antihypertensive drug group that was given.
CONCLUSION: As the overall situation regarding the treatment of hypertension remains inadequate, an aggressive approach to applying the evidence-based guidelines is essential. The underlying causes of this unacceptable degree of hypertension control requires further intensive investigation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17096304     DOI: 10.1055/s-2006-956253

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  16 in total

1.  A pseudo-quality assurance fig leaf.

Authors:  Akhil Chandra
Journal:  Dtsch Arztebl Int       Date:  2012-04-27       Impact factor: 5.594

2.  Treatment of hypertension in Germany: is there a social gradient?

Authors:  Ulrich Laaser; Jürgen Breckenkamp; Vesna Bjegovic
Journal:  Int J Public Health       Date:  2011-07-07       Impact factor: 3.380

3.  [Prevalence of arterial hypertension in the population of Western Germany: Heinz Nixdorf Recall Study].

Authors:  M Horacek; S Möhlenkamp; A A Mahabadi; S Churzidse; S Moebus; K-H Jöckel; R Erbel
Journal:  Herz       Date:  2012-11       Impact factor: 1.443

4.  An inter-state comparison of cardiovascular risk factors in Germany: towards an explanation of high ischemic heart disease mortality in Saxony-Anhalt.

Authors:  Andreas Stang; Maximilian Stang
Journal:  Dtsch Arztebl Int       Date:  2014-08-04       Impact factor: 5.594

5.  [Blood pressure measurement in the NAKO German National Cohort (GNC) - differences in methods, distribution of blood pressure values, and awareness of hypertension compared to other population-based studies in Germany].

Authors:  Tamara Schikowski; Claudia Wigmann; Kateryna B Fuks; Sabine Schipf; Margit Heier; Hannelore Neuhauser; Giselle Sarganas; Wolfgang Ahrens; Heiko Becher; Klaus Berger; Hermann Brenner; Stefanie Castell; Antje Damms-Machado; Marcus Dörr; Nina Ebert; Ljupcho Efremov; Carina Emmel; Stephan B Felix; Beate Fischer; Claus-Werner Franzke; Sylvia Gastell; Kathrin Günther; Johannes Haerting; Till Ittermann; Lina Jaeschke; Annika Jagodzinski; Karl-Heinz Jöckel; Rudolphe Kaaks; Sonja Kalinowski; Thomas Keil; Yvonne Kemmling; Alexander Kluttig; Lilian Krist; Oliver Kuss; Nicole Legath; Michael Leitzmann; Wolfgang Lieb; Markus Löffler; Claudia Meinke-Franze; Karin B Michels; Rafael Mikolajczyk; Susanne Moebus; Sebastian Nuding; Annette Peters; Tobias Pischon; Ina-Maria Rückert-Eheberg; Ben Schöttker; Börge Schmidt; Carsten Oliver Schmidt; Matthias B Schulze; Andreas Stang; Inke Thiele; Sigrid Thierry; Barbara Thorand; Henry Völzke; Sabina Waniek; Karl Werdan; Kerstin Wirkner; Karin Halina Greiser
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2020-04       Impact factor: 1.513

Review 6.  Treatment strategies for resistant arterial hypertension.

Authors:  Felix Mahfoud; Frank Himmel; Christian Ukena; Heribert Schunkert; Michael Böhm; Joachim Weil
Journal:  Dtsch Arztebl Int       Date:  2011-10-28       Impact factor: 5.594

7.  [Renal denervation: current state and future perspectives].

Authors:  K Kara; H Bruck; P Kahlert; B Plicht; A A Mahabadi; T Konorza; R Erbel
Journal:  Herz       Date:  2012-11       Impact factor: 1.443

Review 8.  Treatment resistant hypertension--investigation and conservative management.

Authors:  Franz Weber; Manfred Anlauf
Journal:  Dtsch Arztebl Int       Date:  2014-06-20       Impact factor: 5.594

9.  Clinical application of interventional renal sympathetic denervation: recommendations of the Austrian Society of Hypertension 2012.

Authors:  Thomas Weber; Robert Zweiker; Bruno Watschinger; Peter Grüner; Christian Koppelstätter; Mathias C Brandt; Jörg Horina; Helmut Brussee; Katharina Hohenstein; Thomas Lambert; Johann Auer; Uta C Hoppe
Journal:  Wien Klin Wochenschr       Date:  2012-11-27       Impact factor: 1.704

10.  Catheter-based renal sympathetic denervation improves central hemodynamics and arterial stiffness: a pilot study.

Authors:  Kai Mortensen; Klaas Franzen; Frank Himmel; Frank Bode; Heribert Schunkert; Joachim Weil; Michael Reppel
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-09-11       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.